Drug Trial Radar · NCT02142153
F901318 Single Ascending Dose Study in Healthy Male Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 2014
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Simbec Research
- First posted
- May 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
Conditions
- Invasive Aspergillosis
Interventions
F901318Drug
Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities. Pharmacokinetic profile
PlaceboDrug
Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Adverse EventsTime frame: Single dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec Research
Merthyr Tydfil, Mid Glamorgan, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.